Ligand Pharmaceuticals, Inc. - Class B logo

LGND

Ligand Pharmaceuticals, Inc. - Class B

$104.1

Earnings Summary

Revenue
$45.69Mn
Net Profits
$-15.39Mn
Net Profit Margins
-33.67%
PE Ratio
73

Highlights

Revenue:

Ligand Pharmaceuticals, Inc. - Class B’s revenue fell -17.15% since last year same period to $45.69Mn in the Q1 2022. On a quarterly growth basis, Ligand Pharmaceuticals, Inc. - Class B has generated -36.95% fall in its revenue since last 3-months.

Net Profits:

Ligand Pharmaceuticals, Inc. - Class B’s net profit fell -184.97% since last year same period to $-15.39Mn in the Q1 2022. On a quarterly growth basis, Ligand Pharmaceuticals, Inc. - Class B has generated -209.68% fall in its net profits since last 3-months.

Net Profit Margins:

Ligand Pharmaceuticals, Inc. - Class B’s net profit margin fell -202.56% since last year same period to -33.67% in the Q1 2022. On a quarterly growth basis, Ligand Pharmaceuticals, Inc. - Class B has generated -391.18% fall in its net profit margins since last 3-months.

PE Ratio:

Ligand Pharmaceuticals, Inc. - Class B’s price-to-earnings ratio after this Q1 2022 earnings stands at 73.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ligand Pharmaceuticals, Inc. - Class B post its latest quarter earnings

EPS Estimate Current Quarter
0.43
EPS Estimate Current Year
0.43

Highlights

EPS Estimate Current Quarter:

Ligand Pharmaceuticals, Inc. - Class B’s earning per share (EPS) estimates for the current quarter stand at 0.43 - a -34.85% fall from last quarter’s estimates.

EPS Estimate Current Year:

Ligand Pharmaceuticals, Inc. - Class B’s earning per share (EPS) estimates for the current year stand at 0.43.

Key Ratios

Key ratios of the Ligand Pharmaceuticals, Inc. - Class B post its Q1 2022 earnings

Earning Per Share (EPS)
0.76
Return on Assets (ROA)
0.01
Return on Equity (ROE)
-0.01
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Ligand Pharmaceuticals, Inc. - Class B’s earning per share (EPS) fell -46.1% since last year same period to 0.76 in the Q1 2022. This indicates that the Ligand Pharmaceuticals, Inc. - Class B has generated -46.1% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ligand Pharmaceuticals, Inc. - Class B’s return on assets (ROA) stands at 0.01.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ligand Pharmaceuticals, Inc. - Class B’s return on equity (ROE) stands at -0.01.

Dividend Per Share (DPS):

Ligand Pharmaceuticals, Inc. - Class B declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
0.66
0.76
15.15%

Company Information

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.

Organisation
Ligand Pharmaceuticals, Inc. - Class B
Headquarters
San Diego, California, US
Employees
2.02K
Industry
Health Technology
CEO
John Higgins